Ethionamide indications and usage: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) |
||
| Line 5: | Line 5: | ||
==Indications and Usage== | ==Indications and Usage== | ||
Trecator is primarily indicated for the treatment of active [[tuberculosis]] in patients with M. tuberculosis resistant to [[isoniazid]] or [[rifampin]], or when there is intolerance on the part of the patient to other drugs. Its use alone in the treatment of tuberculosis results in the rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility tests. If the susceptibility tests indicate that the patient's organism is resistant to one of the first-line antituberculosis drugs (i.e., isoniazid or rifampin) yet susceptible to ethionamide, ethionamide should be accompanied by at least one drug to which the M. tuberculosis isolate is known to be susceptible. | Trecator is primarily indicated for the treatment of active [[tuberculosis]] in patients with M. tuberculosis resistant to [[isoniazid]] or [[rifampin]], or when there is intolerance on the part of the patient to other drugs. Its use alone in the treatment of tuberculosis results in the rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility tests. If the susceptibility tests indicate that the patient's organism is resistant to one of the first-line antituberculosis drugs (i.e., isoniazid or rifampin) yet susceptible to ethionamide, ethionamide should be accompanied by at least one drug to which the M. tuberculosis isolate is known to be susceptible. If the tuberculosis is resistant to both isoniazid and rifampin, yet susceptible to ethionamide, ethionamide should be accompanied by at least two other drugs to which the M. tuberculosis isolate is known to be susceptible. | ||
Patient nonadherence to prescribed treatment can result in treatment failure and in the development of drug-resistant tuberculosis, which can be life-threatening and lead to other serious health risks. It is, therefore, essential that patients adhere to the drug regimen for the full duration of treatment. Directly observed therapy is recommended for all patients receiving treatment for tuberculosis. Patients in whom drug-resistant M. tuberculosis organisms are isolated should be managed in consultation with an expert in the treatment of drug-resistant tuberculosis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TRECATOR (ETHIONAMIDE) TABLET, FILM COATED [WYETH PHARMACEUTICALS COMPANY, A SUBSIDIARY OF PFIZER INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04a413fe-95f4-47a7-42ac-283a9e78297d | publisher = | date = | accessdate }}</ref> | Patient nonadherence to prescribed treatment can result in treatment failure and in the development of drug-resistant tuberculosis, which can be life-threatening and lead to other serious health risks. It is, therefore, essential that patients adhere to the drug regimen for the full duration of treatment. Directly observed therapy is recommended for all patients receiving treatment for tuberculosis. Patients in whom drug-resistant M. tuberculosis organisms are isolated should be managed in consultation with an expert in the treatment of drug-resistant tuberculosis.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = TRECATOR (ETHIONAMIDE) TABLET, FILM COATED [WYETH PHARMACEUTICALS COMPANY, A SUBSIDIARY OF PFIZER INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=04a413fe-95f4-47a7-42ac-283a9e78297d | publisher = | date = | accessdate }}</ref> | ||
Latest revision as of 02:58, 31 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Indications and Usage
Trecator is primarily indicated for the treatment of active tuberculosis in patients with M. tuberculosis resistant to isoniazid or rifampin, or when there is intolerance on the part of the patient to other drugs. Its use alone in the treatment of tuberculosis results in the rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility tests. If the susceptibility tests indicate that the patient's organism is resistant to one of the first-line antituberculosis drugs (i.e., isoniazid or rifampin) yet susceptible to ethionamide, ethionamide should be accompanied by at least one drug to which the M. tuberculosis isolate is known to be susceptible. If the tuberculosis is resistant to both isoniazid and rifampin, yet susceptible to ethionamide, ethionamide should be accompanied by at least two other drugs to which the M. tuberculosis isolate is known to be susceptible.
Patient nonadherence to prescribed treatment can result in treatment failure and in the development of drug-resistant tuberculosis, which can be life-threatening and lead to other serious health risks. It is, therefore, essential that patients adhere to the drug regimen for the full duration of treatment. Directly observed therapy is recommended for all patients receiving treatment for tuberculosis. Patients in whom drug-resistant M. tuberculosis organisms are isolated should be managed in consultation with an expert in the treatment of drug-resistant tuberculosis.[1]
References
- ↑ "TRECATOR (ETHIONAMIDE) TABLET, FILM COATED [WYETH PHARMACEUTICALS COMPANY, A SUBSIDIARY OF PFIZER INC.]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.